ArticleOncogene2004
Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Lymphoma dissemination is a pathological hallmark for malignant progression of B-cell lymphoma.Frontiers in immunology · 2023Article
- Peli1 Modulates the Subcellular Localization and Activity of Mdmx.Cancer research · 2018Article
- Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma.Cancer medicine · 2017Article
- Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.Oncogene · 2015Article
- The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.Human mutation · 2014Review
- Biological significance of promoter hypermethylation of p14/ARF gene: relationships to p53 mutational status in Tunisian population with colorectal carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.PloS one · 2012Article
- Article
- Article
- A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition.Molecular and cellular biology · 2011Article
- A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.Oncogene · 2010Article
- Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.Molecular cancer research : MCR · 2010Article
- Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.Neoplasia (New York, N.Y.) · 2009Article
- Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.Cancer cell · 2009Article
- Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.Oncogene · 2008Article
- Article
- Article
- Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo.Oncogene · 2005Article
- Haploinsufficient tumor suppressor genes.Advances in medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The tumor suppressor p19ARF inhibits Mdm2, which restricts the activity of p53. Complicated feedback and control mechanisms regulate ARF, Mdm2, and p53 interactions. Here we report that ARF haploinsufficiency completely rescued the p53-dependent effects of Mdm2 haploinsufficiency on B-cell development, survival, and transformation. In contrast to Mdm2+/- B cells, Mdm2+/- B cells deficient in ARF were similar to wild-type B cells in their rates of growth and apoptosis and activation of p53. Consequently, the profoundly reduced numbers of B cells in Mdm2+/-Emu-myc transgenic mice were restored to normal levels in ARF+/-Mdm2+/-Emu-myc transgenics. Additionally, ARF+/-Mdm2+/-Emu-myc transgenics developed lymphomas at rates analogous to those observed for wild-type Emu-myc transgenics, demonstrating that loss of one allele of ARF rescued the protracted lymphoma latency in Mdm2+/-Emu-myc transgenics. Importantly, in ARF+/-Mdm2+/-Emu-myc transgenic lymphomas, p53 was inactivated at the frequency observed in lymphomas of wild-type Emu-myc transgenics. Collectively, these results support a model whereby the stoichiometry of Mdm2 and ARF controls apoptosis and tumor development, which should have significant implications in the treatment of malignancies that have inactivated ARF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.